• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 4. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 5. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007

3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde: A Versatile Scaffold in Synthetic Chemistry and Pharmaceutical Applications

3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde represents a key intermediate in the development of novel therapeutic agents, with its unique structural framework enabling diverse chemical modifications. The compound features a benzaldehyde group attached to a 4-methyl-1-piperazinyl moiety, with a bromine atom at the 3-position of the aromatic ring. This combination of functional groups provides opportunities for selective chemical transformations, making it a valuable scaffold in the synthesis of bioactive molecules. Recent advances in medicinal chemistry have highlighted the utility of such compounds in targeting specific biological pathways, particularly in the context of pharmaceutical applications.

The 4-methyl-1-piperazinyl substituent in 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde introduces steric and electronic effects that influence its reactivity. Piperazine derivatives are well-known for their ability to modulate ion channels and neurotransmitter systems, which has driven extensive research into their potential as drug candidates. The bromine atom at the 3-position serves as a versatile electrophilic site, facilitating reactions such as nucleophilic substitution, cross-coupling, and heteroaromatization. These properties make 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde a critical building block in the design of compounds with tailored pharmacological profiles.

Recent studies have demonstrated the synthetic utility of 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde in the development of antimicrobial agents and anti-inflammatory drugs. For instance, a 2023 publication in *Journal of Medicinal Chemistry* reported the use of this compound as a precursor for synthesizing derivatives with potent activity against multidrug-resistant bacterial strains. The benzaldehyde group was modified to incorporate fluorinated side chains, enhancing the compound's ability to disrupt bacterial cell membranes. This work underscores the importance of 4-methyl-1-piperazinyl moieties in improving the selectivity and efficacy of antimicrobial agents.

In the realm of pharmaceutical applications, 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde has also been explored for its potential in neurological disorders. A 2024 study published in *ACS Chemical Biology* investigated the use of this compound to develop molecules targeting the NMDA receptor. The 4-methyl-1-piperazinyl group was found to interact with specific amino acid residues in the receptor, modulating its activity and reducing excitotoxicity. These findings highlight the compound's role in the design of neuroprotective agents and its relevance to the treatment of conditions such as epilepsy and neurodegenerative diseases.

3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde is also being studied for its potential in cancer therapy. Researchers at the University of Tokyo have reported the synthesis of derivatives with antitumor activity against pancreatic cancer cells. The benzaldehyde group was functionalized with a piperazine ring containing a methyl substituent, enhancing the compound's ability to inhibit cell proliferation. This work aligns with growing interest in piperazine-based compounds for their ability to target specific signaling pathways involved in tumor progression.

From a synthetic perspective, the preparation of 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde involves a multi-step process that combines aromatic substitution and piperazine ring formation. A 2022 paper in *Organic Letters* described an efficient route to this compound using a Suzuki-Miyaura coupling reaction, which allowed for the selective introduction of the bromine atom. This method has since been adopted in several industrial-scale syntheses, demonstrating the compound's scalability and cost-effectiveness.

3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde has also been explored as a precursor for the synthesis of heterocyclic compounds, which are commonly used in drug discovery. A 2023 study in *Tetrahedron* reported the use of this compound to create thiazole derivatives with enhanced antiviral activity. The 4-methyl-1-piperazinyl group was incorporated into the thiazole ring, improving the compound's ability to inhibit viral replication. This work highlights the versatility of 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde in generating novel bioactive molecules.

Environmental and safety considerations are also critical in the use of 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde. While the compound itself is not classified as a hazardous substance, its derivatives may exhibit varying degrees of toxicity. A 2024 review in *Green Chemistry* emphasized the importance of green synthesis methods in reducing the environmental impact of piperazine-based compounds. This includes the use of catalytic processes and solvent-free conditions to minimize waste and energy consumption during synthesis.

Looking ahead, the 4-methyl-1-piperazinyl group in 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde is expected to play an increasingly important role in the development of targeted therapies. Advances in computational chemistry and molecular modeling are enabling researchers to predict the interactions of benzaldehyde derivatives with biological targets, further optimizing their pharmacological properties. These innovations are likely to expand the pharmaceutical applications of 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde in the coming years.

In conclusion, 3-Bromo-4-(4-methyl-1-piperazinyl)benzaldehyde is a multifunctional compound with significant potential in pharmaceutical applications. Its unique structural features, including the benzaldehyde group and 4-methyl-1-piperazinyl substituent, make it a valuable scaffold for the synthesis of bioactive molecules. Ongoing research into its synthetic utility and biological activity is expected to yield further insights into its role in the development of novel therapeutic agents.

• 628325-60-0(5-Bromo-2-(4-methylpiperazin-1-yl)benzaldehyde)
• 1131594-67-6(3-bromo-4-(Piperazin-1-yl)benzoic acid)
• 443777-04-6(4-(4-BENZYL-1-PIPERAZINO)-3-BROMO-BENZALDEHYDE)
• 532440-31-6(Benzaldehyde, 3-bromo-4-(ethylamino)-)
• 628325-61-1(2-Bromo-5-(4-methylpiperazin-1-yl)benzaldehyde)
• 56479-63-1(3-Bromo-4-(dimethylamino)benzaldehyde)
• 1131594-62-1(3-Bromo-4-(4-ethylpiperazin-1-yl)benzoic acid)
• 1131594-08-5(3-Bromo-4-(diethylamino)benzoic acid)
• 1131622-55-3(3-Bromo-4-(4-methylpiperazin-1-yl)benzoic acid)
• 1131594-70-1(3-Bromo-4-(4-isopropylpiperazin-1-yl)benzoic acid)